BR0303092A - Portfólio para prognóstico de câncer de mama - Google Patents

Portfólio para prognóstico de câncer de mama

Info

Publication number
BR0303092A
BR0303092A BR0303092-0A BR0303092A BR0303092A BR 0303092 A BR0303092 A BR 0303092A BR 0303092 A BR0303092 A BR 0303092A BR 0303092 A BR0303092 A BR 0303092A
Authority
BR
Brazil
Prior art keywords
breast cancer
portfolio
cancer prognosis
genes
gene
Prior art date
Application number
BR0303092-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Yixin Wang
Original Assignee
Johnson & Johnson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29215884&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0303092(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Johnson & Johnson filed Critical Johnson & Johnson
Publication of BR0303092A publication Critical patent/BR0303092A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/112Disease subtyping, staging or classification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
BR0303092-0A 2002-03-29 2003-03-28 Portfólio para prognóstico de câncer de mama BR0303092A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36878902P 2002-03-29 2002-03-29

Publications (1)

Publication Number Publication Date
BR0303092A true BR0303092A (pt) 2004-09-08

Family

ID=29215884

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0303092-0A BR0303092A (pt) 2002-03-29 2003-03-28 Portfólio para prognóstico de câncer de mama

Country Status (11)

Country Link
US (1) US7473526B2 (enExample)
EP (1) EP1367138B1 (enExample)
JP (1) JP2003325192A (enExample)
KR (1) KR20030078805A (enExample)
CN (1) CN1495274A (enExample)
AR (1) AR039213A1 (enExample)
AU (1) AU2003203557B2 (enExample)
BR (1) BR0303092A (enExample)
CA (1) CA2422303A1 (enExample)
DE (1) DE60317606T2 (enExample)
MX (1) MXPA03002864A (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1361433A3 (en) * 2002-04-09 2005-02-23 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Method for estimating therapeutic efficacy of tumor necrosis factor (TNF)
US20050003422A1 (en) * 2003-07-01 2005-01-06 Mitch Reponi Methods for assessing and treating cancer
JP5089993B2 (ja) * 2004-02-20 2012-12-05 ベリデックス・エルエルシー 乳癌の予後診断
JP2007532142A (ja) * 2004-04-23 2007-11-15 エグザジェン ダイアグノスティクス インコーポレイテッド 乳がん遺伝子発現バイオマーカー
US20070130694A1 (en) * 2005-12-12 2007-06-14 Michaels Emily W Textile surface modification composition
EP2380978A3 (en) * 2006-02-03 2012-02-29 MessengerScape Co. Ltd. Gene group applicable to cancer prognostication
BRPI0720219A2 (pt) 2006-12-08 2013-12-24 Univ Iowa State Res Found Inc Genes de planta envolvidos em absorção e metabolismo de nitrato
CN105224827B (zh) * 2008-07-01 2019-12-24 小利兰·斯坦福大学托管委员会 用于发展ivf治疗协议的分析数据的计算机系统和存储介质
ES2338843B1 (es) * 2008-07-02 2011-01-24 Centro De Investigaciones Energeticas, Medioambientales Y Tecnologicas Huella genomica de cancer de mama.
GB0821787D0 (en) * 2008-12-01 2009-01-07 Univ Ulster A genomic-based method of stratifying breast cancer patients
US8790916B2 (en) 2009-05-14 2014-07-29 Genestream, Inc. Microfluidic method and system for isolating particles from biological fluid
US10011876B2 (en) 2010-11-23 2018-07-03 Krisani Biosciences Pvt. Ltd Method and system for prognosis and treatment of diseases using portfolio of genes
KR101287600B1 (ko) * 2011-01-04 2013-07-18 주식회사 젠큐릭스 초기유방암의 예후 예측용 유전자 및 이를 이용한 초기유방암의 예후예측 방법

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US635152A (en) * 1899-06-05 1899-10-17 Melancthon S Shotwell Car-body bolster.
US6350576B1 (en) 1994-12-20 2002-02-26 Cold Spring Harbor Laboratory Cancer detection probes
AU5310296A (en) 1995-03-17 1996-10-08 John Wayne Cancer Institute Detection of melanoma or breast metastases with a multiple marker assay
US6275814B1 (en) 1996-11-27 2001-08-14 Investment Strategies Network Investment portfolio selection system and method
US6003018A (en) 1998-03-27 1999-12-14 Michaud Partners Llp Portfolio optimization by means of resampled efficient frontiers
US6037129A (en) 1998-05-28 2000-03-14 Medical University Of South Carolina Multi-marker RT-PCR panel for detecting metastatic breast cancer
US6175624B1 (en) * 1999-03-05 2001-01-16 Centurion International, Inc. Method for connecting a battery circuit in a cellular telephone
MXPA01009369A (es) 1999-03-15 2003-06-06 Eos Biotechnology Inc Nuevos metodos para el diagnostico del cancer colorectal, composiciones, y metodos para seleccionar moduladores del cancer colorectal.
JP2004507202A (ja) * 1999-03-31 2004-03-11 キュラジェン コーポレイション ポリペプチドをコードするオープンリーディングフレームを含む核酸;「orfx」
US6175824B1 (en) 1999-07-14 2001-01-16 Chi Research, Inc. Method and apparatus for choosing a stock portfolio, based on patent indicators
RU2251838C2 (ru) 1999-07-15 2005-05-20 Рисерч Дивелопмент Фаундейшн Способ получения неприродной трансгенной мыши с дефицитом гена рецептора 2 кортиколиберина и ее использование
WO2003070889A2 (en) * 2002-02-19 2003-08-28 Idec Pharmaceuticals Corporation Prostate specific genes and the use thereof in design or therapeutics
US20050054826A1 (en) * 2003-05-19 2005-03-10 Rosetta Inpharmatics Llc Human diaphanous-3 gene and methods of use therefor

Also Published As

Publication number Publication date
CA2422303A1 (en) 2003-09-29
AU2003203557B2 (en) 2007-05-24
DE60317606D1 (de) 2008-01-03
KR20030078805A (ko) 2003-10-08
EP1367138A2 (en) 2003-12-03
US20030190656A1 (en) 2003-10-09
US7473526B2 (en) 2009-01-06
JP2003325192A (ja) 2003-11-18
AU2003203557A1 (en) 2003-10-23
DE60317606T2 (de) 2008-10-23
AR039213A1 (es) 2005-02-09
EP1367138A3 (en) 2004-03-10
CN1495274A (zh) 2004-05-12
MXPA03002864A (es) 2004-08-11
EP1367138B1 (en) 2007-11-21

Similar Documents

Publication Publication Date Title
BR0303011A (pt) Painel de diagnóstico de câncer
BR0303092A (pt) Portfólio para prognóstico de câncer de mama
Rasiah et al. Prognostic significance of Gleason pattern in patients with Gleason score 7 prostate carcinoma
MüLLER et al. Prognostic DNA methylation marker in serum of cancer patients
Seuk Kim et al. Aberrant methylation of H‐cadherin (CDH13) promoter is associated with tumor progression in primary nonsmall cell lung carcinoma
ATE470723T1 (de) Genexpressionsmarker für die prognose von brustkrebs
WO2003021227A3 (en) Methods and compositions useful for diagnosis, staging, and treatment of cancers and tumors
Szczepanowski et al. Cell‐of‐origin classification by gene expression and MYC‐rearrangements in diffuse large B‐cell lymphoma of children and adolescents
Salcedo-Hernández et al. Synovial sarcomas of the head and neck: comparative analysis with synovial sarcoma of the extremities
AR043808A1 (es) Pronostico de cancer colorrectal
DE69507470D1 (de) Diagnose von krebs, dessen zellen das am tyrosin phosphorylierte crkl-protein exprimieren
EP1090294A4 (en) METHOD FOR DETERMINING THE PRESENCE OF CANCER IN A SAMPLE BY DETECTING THE EXPRESSION OF A SSX GENE AND PEPTIDES DERIVED FROM SSX OR NY-ESO-1
AR044099A1 (es) Pronostico de cancer de mama
Cocciadiferro et al. Profiling cancer stem cells in androgen‐responsive and refractory human prostate tumor cell lines
EP1226153A4 (en) FLUORESCENT COBALAMINES AND ITS USE
GE4GAC group et al. Genomics and epidemiology for gastric adenocarcinomas (GE4GAC): a Brazilian initiative to study gastric cancer
PT1058739E (pt) Metodo para produzir perfis de expressao genica
CY1115258T1 (el) Μεθοδοι και χρησεις που περιλαμβανουν τις γενετικες παρεκκλισεις του ναv3 και την παρεκκλινουσα εκφραση πολλαπλων γονιδιων
Krüger et al. Prognostic significance of a grading system considering tumor heterogeneity in muscle-invasive urothelial carcinoma of the urinary bladder
ATE256120T1 (de) Reagentien für cyp2d fluoreszenztest
Kleen et al. Quantitative real-time PCR assisted cell counting (qPACC) for epigenetic-based immune cell quantification in blood and tissue
Garber At loose ends: telomere theories of aging and cancer begin to converge
Hamzeh et al. Finding transcripts associated with prostate cancer gleason stages using next generation sequencing and machine learning techniques
IL126257A (en) Immuno-magnetic cell separation for use in identification of genes associated with site-preferenced cancer methastasis formation
Rykova et al. Methylation‐Based Analysis of Circulating DNA for Breast Tumor Screening

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A E 7A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2042 DE 23/02/2010.